A study of a new medicine to prevent fever in children on chemotherapy
Treatments studied
Part of Cancer clinical trials.
This study tests a new medicine called Telpegfilgrastim to help prevent fever from low white blood cell counts in children (14–17) with certain cancers who are getting strong chemotherapy. It aims to see if the medicine is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 18 years old (but not yet 18).
- You have a type of cancer that does not start in the bone marrow or lymph system, such as solid tumors.
- You are getting intensive chemotherapy and need a medicine (G-CSF) to prevent fever caused by low white blood cell counts, either for the first time or because you had fever or low counts in a previous round.
- You are generally able to do daily activities even if you need rest (score 50 or higher on a 0–100 scale).
- Your blood counts (white blood cells, platelets, and hemoglobin) are within healthy ranges, and your liver and kidney function tests are normal or only slightly high.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drugs (Telpegfilgrastim and Filgrastim) to help prevent dangerously low white blood cell counts after chemotherapy in children and young adults with solid tumors. It's for patients who have already had this problem in a previous chemo round.
This trial tests a once-per-cycle injection (Telpegfilgrastim) to help keep your white blood cell count from dropping dangerously low during chemotherapy. It is for people with solid tumors who are at increased risk for neutropenia (low infection-fighting cells).
This trial tests a medication that aims to reduce the risk of dangerously low white blood cell counts (neutropenia) after chemotherapy combined with immunotherapy for certain advanced lung or esophageal cancers. It may help prevent infections and other complications, making treatment safer.
This study looks at whether a common side effect (bone pain) from a medicine that boosts white blood cells (called G-CSF) is related to the number of neutrophils (a type of white blood cell) in your blood. If you join, you will receive the medicine as part of your normal chemotherapy routine, and the researchers will track your blood counts and any bone pain you experience.
This study compares different doses of a medication called PEG-rhG-CSF, which is used to help prevent a serious side effect of chemotherapy called febrile neutropenia (fever with a low white blood cell count). The goal is to find the best dose that keeps your blood counts healthy and reduces the risk of infection during treatment.
This study tests a drug (me capegfilgrastim) given as a shot to help prevent a dangerous drop in white blood cells and fever during chemotherapy. It is for people with cancer who are at high risk for this side effect.
Hear when a new Chemotherapy-induced Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.